Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed on the Copenhagen stock exchange and on NASDAQ in the…
Since joining Danish neuroscience specialist Lundbeck as its global CEO in 2018, South African Deborah Dunsire has focused on “revitalising and refreshing” the firm’s pipeline, which had seen several failures…
Although Zealand Pharma has been around for 23 years, it has made rapid progress since French national Emmanuel Dulac took the helm as president and CEO in April 2019, with…
Denmark has long been at the vanguard of digitalisation, most notably in the form of comprehensive national health registries. This well-established footprint gave the Nordic nation a headstart in battling…
Lars Georg Rust outlines Olympus’ transition into fully-fledged MedTech company, the relevance of the Nordics and Netherlands to the global group, and some areas for improvement within the Danish hospital…
GN Hearing CEO Gitte Aabo highlights the significant unmet needs of hearing impairment patients, the role of private companies like GN in fighting against stigmas surrounding hearing aids, the digital…
Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is…
Data has been collected within Danish healthcare for more than 40 years, extending beyond the national patient registry to include a broad range of data points, from IVF to the…
Denmark’s four largest pharma companies – Novo Nordisk, Lundbeck, LEO Pharma, and ALK – are all at least partly owned by independent foundations, which means that their profits are divided…
Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international…
The DKK 56bn (EUR 7.5bn) Danish medtech industry employs 15,200 workers, accounts for 7.4 percent of Danish business and industry’s total research investments, contributes to 1.4 percent of national GDP,…
Catherine Mazzacco’s two-year stint as CEO of Danish dermatology specialist LEO Pharma is over. With the company’s board planning for an initial public offering (IPO) within the next four-to-five years,…
Speaking after the recent completion of a three-year strategic transformation plan, ALK President and CEO Carsten Hellmann outlines the progress made by the Danish allergy giant under his stewardship, including…
See our Cookie Privacy Policy Here